Compound Guides
In-depth research on individual peptides — mechanisms of action, clinical evidence, purity considerations, and how to evaluate lab results for each compound.
How to Read a Peptide COA
A complete guide to reading and evaluating a Certificate of Analysis — what HPLC purity and mass spectrometry results actually mean, red flags to watch for, and how to verify a COA is legitimate.
BPC-157
Body Protection Compound-157 — mechanism of action, research evidence, limitations, and what to look for in lab testing and purity analysis.
GHK-Cu (Copper Peptide)
Naturally occurring copper-binding tripeptide — 50+ years of research on skin aging, wound healing, and tissue repair. Purity and lab testing considerations.
TB-500 (Thymosin Beta-4)
The naming confusion between TB-500 and full-length Thymosin Beta-4, mechanism of action, research evidence, and why mass spec is critical for this compound.
Semaglutide
FDA-approved GLP-1 receptor agonist — clinical evidence, pharmaceutical vs. compounded versions, evolving regulatory landscape, and lab testing to detect substitution.
CJC-1295
GHRH analog available in two forms — with DAC (sustained release, ~3,647 Da) and without DAC (~3,367 Da, pulsatile). Phase 1 human data, mechanism, and lab testing.
Ipamorelin
The first selective growth hormone secretagogue — GH release without cortisol or prolactin spikes. Selectivity comparison table, CJC-1295 combination, and lab testing.
Tirzepatide
First dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound). Superior to semaglutide in head-to-head trials. Clinical evidence, compounding landscape, and lab testing.